Photo: newsable.asianetnews.com
ASP Isotopes Shares Jump 13% on Major Silicon-28 Deal and Radiopharmacy Acquisition
ASP Isotopes Inc. secured a significant enriched silicon-28 supply deal and a radiopharmacy acquisition, positioning itself for growth in the nuclear pharmacy sector in South Africa.
- ASP Isotopes Inc. signed its largest supply deal for enriched silicon-28, with shipments expected to begin in the first quarter of 2026.
- The acquisition of a U.S.-based radiopharmacy is set to enhance ASP Isotopes capabilities in the production of radiopharmaceuticals and support its South African subsidiary, PET Labs.
- This strategic move aims to boost ASP Isotopes revenues, EBITDA, and EPS for 2026, emphasizing the importance of materials science in their business expansion.
Why It Matters
This development reflects a growing investment in the nuclear pharmacy sector, which is crucial for advancements in medical technologies and treatments, particularly in South Africa. The enhanced supply of isotopes and radiopharmaceuticals could significantly impact healthcare outcomes in the region.